Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis
Obesity · 2026-05 · 34 (5) · 1010-1019
DOI: 10.1002/oby.70183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 31.03.2026. Verfasst von Jena Shaw Tronieri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsy…. Hauptthemen laut MEDLINE: Naltrexone, Bupropion, Obesity, Depression. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Currax Pharmaceuticals, LLC.
Themen: Depression
Abstract (Originalsprache)
Objective
The present study examined the safety and efficacy of the fixed‐dose, extended‐release combination of naltrexone and bupropion (NB‐ER) in individuals with overweight/obesity and mild to moderate symptoms of depression.
Methods
Data were pooled from four double‐blind, placebo‐controlled trials. Participants with baseline Inventory of Depressive Symptomatology—Self‐Report scores ≥ 14 suggestive of mild or greater depressive symptoms were included ( N = 511). Primary outcomes were 56‐week percent weight loss and changes in depression, as well as safety data for psychiatric adverse events (PAEs), depressive symptom increases, and suicidal ideation. Multiple imputation was applied, and outcomes were compared in the intention‐to‐treat population.
Results
In participants with symptoms of depression, 56‐week weight loss was significantly greater with NB‐ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003). Participants experienced clinically meaningful improvements in depression of −7.1 ± 0.4 with NB‐ER and −6.7 ± 0.5 with placebo, with no significant differences between the groups. NB‐ER and placebo did not differ in safety signals including PAE occurrence (27.5% NB‐ER vs. 22.1% placebo), depressive symptom increases (9.5% NB‐ER vs. 8.8% placebo), or suicidal ideation (1.8% NB‐ER vs. 2.0% placebo).
Conclusions
NB‐ER appears to be both safe and effective for weight loss when offered to patients with mild to moderate symptoms of depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Brigham and Women's Hospital Center for Weight Management and Wellness, Boston, Massachusetts, USA.
- Knownwell, Needham, Massachusetts, USA.
- Geisinger Commonwealth School of Medicine, Danville, Pennsylvania, USA.
ORCID-Profile: Robert F Kushner, Caroline M Apovian, Angela Fitch, Thomas A Wadden
Förderung
- Currax Pharmaceuticals, LLC
Zitieren
APA
Tronieri, J. S., Kushner, R. F., Apovian, C. M., Fitch, A., Still, C., & Wadden, T. A. (2026). Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis. Obesity, 34(5), 1010-1019. https://doi.org/10.1002/oby.70183
Vancouver
Tronieri JS, Kushner RF, Apovian CM, Fitch A, Still C, Wadden TA. Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis. Obesity. 2026;34(5):1010-1019. doi:10.1002/oby.70183
BibTeX
@article{Tronieri2026,
author = {Tronieri, Jena Shaw and Kushner, Robert F and Apovian, Caroline M and Fitch, Angela and Still, Christopher and Wadden, Thomas A},
title = {Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis},
journal = {Obesity},
year = {2026},
volume = {34},
number = {5},
pages = {1010--1019},
doi = {10.1002/oby.70183}
}
EUVIMED